| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
110,116,000 |
| Market
Cap: |
3.96(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$7.07 - $46.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 957 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Scholar Rock is a biopharmaceutical company focused on the discovery and development of medicines for the treatment of serious diseases. Co. has progressed the development of: Apitegromab, an inhibitor of the activation of latent myostatin for the treatment of spinal muscular atrophy; SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies; selective inhibitors of the activation of transforming growth factor beta for the treatment of fibrotic diseases; and additional discovery and early preclinical programs related to the selective modulation of growth factor signaling.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
6,579,493 |
| Total Buy Value |
$0 |
$0 |
$0 |
$45,086,736 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
89,854 |
430,292 |
4,012,252 |
4,140,139 |
| Total Sell Value |
$2,822,242 |
$15,646,181 |
$143,358,921 |
$145,347,704 |
| Total People Sold |
11 |
15 |
17 |
17 |
| Total Sell Transactions |
13 |
30 |
42 |
60 |
| End Date |
2025-04-03 |
2024-12-31 |
2024-07-02 |
2023-07-03 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Flier Jeffrey S. |
|
– • – |
2025-06-23 |
4 |
AS |
$33.21 |
$369,818 |
I/I |
(11,136) |
11,136 |
|
8% |
|
| Flier Jeffrey S. |
|
– • – |
2025-06-23 |
4 |
AS |
$32.16 |
$654,904 |
D/D |
(20,316) |
24,070 |
|
8% |
|
| Flier Jeffrey S. |
|
– • – |
2025-06-23 |
4 |
OE |
$21.62 |
$439,232 |
D/D |
20,316 |
44,386 |
|
- |
|
| Peng Katie |
|
– • – |
2025-06-16 |
4 |
AS |
$31.96 |
$96,888 |
D/D |
(3,031) |
34,920 |
|
11% |
|
| Ho Junlin |
GENERAL COUNSEL |
• – – |
2025-06-16 |
4 |
S |
$32.00 |
$238,154 |
D/D |
(7,442) |
222,569 |
|
-11% |
|
| Parlavecchio Caryn |
CHRO |
• – – |
2025-06-16 |
4 |
S |
$32.00 |
$197,961 |
D/D |
(6,186) |
157,642 |
|
-11% |
|
| Qatanani Mo |
CHIEF SCIENTIFIC OFFICER |
• – – |
2025-06-16 |
4 |
S |
$32.00 |
$117,381 |
D/D |
(3,668) |
139,561 |
|
-11% |
|
| Ho Junlin |
GENERAL COUNSEL |
• – – |
2025-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
8,571 |
230,011 |
|
- |
|
| Reed Joshua |
|
– • – |
2025-05-29 |
4 |
AS |
$29.68 |
$160,463 |
D/D |
(5,400) |
15,732 |
|
20% |
|
| Brudnick Richard |
|
– • – |
2025-05-29 |
4 |
AS |
$29.63 |
$180,531 |
D/D |
(6,075) |
15,057 |
|
20% |
|
| Vaishnaw Akshay |
President of R&D |
• • – |
2025-05-29 |
4 |
AS |
$29.63 |
$200,612 |
D/D |
(6,750) |
616,205 |
|
20% |
|
| Burow Kristina |
|
– • – |
2025-05-29 |
4 |
AS |
$29.24 |
$160,511 |
D/D |
(5,400) |
21,071 |
|
20% |
|
| Flier Jeffrey S. |
|
– • – |
2025-05-29 |
4 |
AS |
$29.23 |
$180,584 |
D/D |
(6,075) |
24,070 |
|
20% |
|
| Gilman Michael |
|
– • – |
2025-05-29 |
4 |
AS |
$29.22 |
$100,304 |
D/D |
(3,375) |
55,216 |
|
20% |
|
| Peng Katie |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
7,632 |
37,951 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
7,632 |
21,132 |
|
- |
|
| Flier Jeffrey S. |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
7,632 |
30,145 |
|
- |
|
| Brudnick Richard |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
7,632 |
21,132 |
|
- |
|
| Gilman Michael |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
7,632 |
58,591 |
|
- |
|
| Burow Kristina |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
7,632 |
26,471 |
|
- |
|
| Reed Joshua |
Director |
– • – |
2025-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
7,632 |
21,132 |
|
- |
|
| Sinha Vikas |
Chief Financial Officer |
• – – |
2025-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
600,000 |
600,000 |
|
- |
|
| Woods Keith |
Chief Operating Officer |
• – – |
2025-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
600,000 |
600,000 |
|
- |
|
| Vaishnaw Akshay |
President of R&D |
• • – |
2025-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
600,000 |
622,955 |
|
- |
|
| Hallal David |
CEO |
• • – |
2025-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500,000 |
1,804,095 |
|
- |
|
212 Records found
|
|
Page 1 of 9 |
|
|
0.44 (1.24%) 
